A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Clinical trial NCT00509769 · COMPLETED
Trial details
- NCT number
- NCT00509769
- Sponsor
- Genentech, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2007-07-01
- Primary completion
- 2009-01-01
- Enrollment
- 112
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.